Other Clinical Trial - Multicenter Cohort of STEMI Patients

Status Recruiting

Clinical Trial Summary

Ischemic heart disease is the leading cause of mortality with 7.2 million of death in industrialized countries (WHO data). Myocardial infarction corresponding to acute occlusion of a coronary artery is the most brutal form and the more severe ischemic myocardial disease. Every year in France, about 60,000 Myocardial infarctions hospitalized, 30,000 are diagnosed remotely and 30,000 are revealed by an inaugural sudden death. Although mortality from myocardial decreased by 30% over the past decade, the prognosis is pejorative and difficult to assess precisely. The management of the patient depends on these factors, and justifies an active search on these topics, including the mechanisms of the deleterious ventricular remodeling, myocardial inflammation, reperfusion injury which determines in particular the evolution to heart failure. Cohorts of patients with myocardial infarction are rare but can be very valuable by their clinical, laboratory and imaging well documented. They are the source of new hypotheses for research or interventions as well as the quality of care assessment tool. The main objective of this project is to identify new markers: biological and imaging, treatment response and prognosis after acute myocardial infarction. Secondary objectives of the HIBISCUS-STEMI cohort to establish a clinical database, completed by biological samples and by imaging data that can be used in the following areas: - Descriptive epidemiology of myocardial infarction and myocardial reperfusion - Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of treatment in real life, costs - Assessment of the long-term effect of the treatment on the occurrence of heart failure and sudden death - Quality of life and personal consequences, family, professional and social myocardial infarction - Research of new diagnostic and prognostic biomarkers - Research projects (e.g. risk of developing kidney failure or stroke in patients with myocardial infarction compared to the general population).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Infarction
Myocardial Infarction
ST Elevation Myocardial Infarction
STEMI - ST Elevation Myocardial Infarction

Clinical Trial Details

NCT number	NCT03070496
Study type	Interventional
Source	Hospices Civils de Lyon
Contact	Michel OVIZE, MD, PhD
Phone	+33 472 357 170
Email	ghe.ciclyon@chu-lyon.fr
Status	Recruiting
Phase	N/A
Start date	March 7, 2017
Completion date	December 7, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06013813` - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI	N/A
Completed	`NCT04542889` - Coronary Microcirculation Assessment After Primary Angioplasty in Myocardial Infarction	N/A
Recruiting	`NCT04951856` - Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI	Phase 4
Terminated	`NCT04459299` - CorPath GRX STEMI Study
Recruiting	`NCT05557019` - Semi Occlusion of the Coronary Sinus as an Adjunct to PCI in STEMI Patients, FIH Clinical Study	N/A
Completed	`NCT03527940` - Prognostic Markers of Patients With STEMI
Not yet recruiting	`NCT03264859` - NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction	N/A
Not yet recruiting	`NCT03182855` - Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI	Phase 4
Not yet recruiting	`NCT03266289` - Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab	N/A
Withdrawn	`NCT04566289` - Observational Registry to Evaluate Real World Usage of PiCSO Impulse System in STEMI Patients as Part of Post-marketing Surveillance
Completed	`NCT04289012` - HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study	N/A
Not yet recruiting	`NCT04185077` - Bivalirudin in Late PCI for Oatients With STEMI	Phase 4
Completed	`NCT03609346` - Asian Registry of the BioFreedom Stent for STEMI Patients
Recruiting	`NCT05107076` - Effect of PPCI on Diastolic Function & Levels of Galactin-3 in Patients With STEMI
Recruiting	`NCT02998853` - Non Culprit Functional Evaluation With 3D Angio QFR in STEMI PCI Procedure	N/A
Completed	`NCT03677180` - National Cardiogenic Shock Initiative
Completed	`NCT03507777` - ILUMIEN IV: OPTIMAL PCI	N/A
Recruiting	`NCT03863327` - EKG Criteria and Identification of Acute Coronary Occlusion
Active, not recruiting	`NCT03874338` - CLEAR SYNERGY Neutrophil Substudy
Withdrawn	`NCT05497011` - A Study to Evaluate the Safety and Efficacy of PiCSO in Anterior STEMI Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Multicenter Cohort of STEMI Patients — HIBISCUS-STEMI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms